

Pozycje naukowe dotyczące aquagenic pruritus

- Auerbach PS. *Auerbach: Wilderness Medicine, 5th ed.*. Philadelphia: Mosby, An Imprint of Elsevier; 2007;
- Reich A, et al.. Drug-induced Pruritus: A Review. *Acta Derm Venereol.* 2009; 89:236-244.<http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-0650&html=1>. Accessed 6/20/2011.
- Greaves MW. Chapter 41 - Pathophysiology and Clinical Aspects of Pruritus. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, . *Fitzpatrick's Dermatology in General Medicine*. PA: PA; 2003;
- Wolf R, Krakowski A. Variations in aquagenic pruritus and treatment alternatives. *J Am Acad Dermatol.* 1988 May;18(5 Pt 1):1081-3;
- Treudler R, Tebbe B, Steinhoff M, Orfanos CE. Familial aquagenic urticaria associated with familial lactose intolerance. *J Am Acad Dermatol.* 2002 Oct;47(4):611-3;
- Heitkemper T, Hofmann T, Phan NQ, Ständer S. Aquagenic pruritus: associated diseases and clinical pruritus characteristics. *J Dtsch Dermatol Ges.* 2010 Oct;8(10):797-804;
- G. Angelini, D. Bonamonte: *Aquatic Dermatology*. Springer Science & Business Media, 2012, s. 10-46.[ISBN 8847020956](#).
- Brian B. Adams: *Sports Dermatology*. Springer Science & Business Media, 2006, s. 181. [ISBN 0387400451](#).
- Henry Harold Friedman: *Problem-oriented Medical Diagnosis*. Lippincott Williams & Wilkins, 2001, s. 30.[ISBN 0781729092](#).
- Steinman HK, Greaves MW: Aquagenic pruritus. *J Am Acad Dermatol* 1985;13:91–96.
- Ryan TJ: Microvascular injury. *Major Problems in Dermatology* 1976;7:49.
- Lotti T, Teofoli P, Tsampau D: Treatment of aquagenic pruritus with topical capsaicin cream. *J Am Acad Dermatol* 1994;30:232–235.
- Carson TE: Aquagenic pruritus: effective treatment with intramuscular triamcinolone acetone. *Cutis* 1991;48:382.
- Menage HD, Norris PG, Hawk JL, Greaves MW: The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. *Br J Dermatol* 1993;129:163–165.

- Woold WE: Dermatologic symptoms without signs. Seeking the cause of itching, pain, and burning.
- *Postgrad Med* 1989, 85(4):369-370.
- Bircher AJ: Water induced itching.
- *Dermatologica* 1990, 181(2):83-87. [PubMed Abstract](#)
- Handfield-Jones SE, Hills RJ, Ive FA, Greaves MW: Aquagenic pruritus associated with juvenile xanthogranuloma.
- *Clin Exp Dermatol* 1993, 18(3):253-255. [PubMed Abstract](#) | [Publisher Full Text](#)
- McGrath JA, Greaves MW: Aquagenic pruritus and myelodysplastic syndrome.
- *Br J Dermatol* 1990, 123(3):414-415. [PubMed Abstract](#) | [Publisher Full Text](#)
- Abdel-Naser MB, Gollnick H, Orfanos CE: Aquagenic pruritus as a presenting symptom of polycythaemia vera.
- *Dermatology* 1993, 187(2):130-133. [PubMed Abstract](#)
- Gerlini G, Prignano F, Pimpinelli N: Acute leucocytoclastic vasculitis and aquagenic pruritus long preceding polycythaemia rubra vera.
- *Eur J Dermatol* 2002, 12(3):270-271. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ratnaval RC, Burrows NP, Marcus RE, Norris PG: Aquagenic pruritus and acute lymphoblastic leukaemia.
- *Br J Dermatol* 1993, 129(3):348-349. [PubMed Abstract](#) | [Publisher Full Text](#)
- Khalifa N, Singer CR, Black AK: Aquagenic pruritus in a patient associated with myelodysplasia and T-cell non-Hodgkin's lymphoma.
- *J Am Acad Dermatol* 2002, 46(1):144-145. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ferguson JE, August PJ, Guy AJ: Aquagenic pruritus associated with metastatic squamous cell carcinoma of the cervix.
- *Clin Exp Dermatol* 1994, 19(3):257-258. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gregor M: Aquagenic pruritus and hepatitis.
- *Internist(Berl)* 1999, 40(2):220-221. [PubMed Abstract](#) | [Publisher Full Text](#)
- Moreno Caballero B, Castro Barrio M, Blanco Andres C: Aquagenic pruritus due to use of bupropion.
- *Aten Primaria* 2002, 30(10):662-663. [PubMed Abstract](#) | [Publisher Full Text](#)
- Jimenez-Alonzo J, Tercedor J, Jaimez L, Garcia-Lora E: Antimalarial drug induced aquagenic pruritus in patients with lupus.
- *Arthritis Rheum* 1998, 41(4):744-745. [PubMed Abstract](#) | [Publisher Full Text](#)

- Newton JA, Singh AK, Greaves MW, Spry CJ: Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome.
- *Br J Dermatol* 1990, 112(1):103-106. [Publisher Full Text](#)
- Greaves MW, Black AK, Eady RA, Coutts A: Aquagenic pruritus.
- *Br Med J Clin Res Ed* 2008, 282(6281):10.
- Ingber S, Cohen PD: Successful treatment of refractory Aquagenic pruritus with Naltrexone.
- *J Cutan Med Surg* 2006, 2. [PubMed Abstract](#)
- Thomsen K: Aquagenic pruritus responds to propranolol.
- *J Am Dermatol* 1990, 22(4):697-698. [Publisher Full Text](#)
- Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A: Treatment of aquagenic urticaria with PUVA and astemizole.
- *J Am Acad Dermatol* 1997, 36(1):118-119. [PubMed Abstract](#) | [Publisher Full Text](#)
- Reinhold U, Hartl C, Gerdson R, Kreysel HW: Treatment of aquagenic pruritus using recombinant interferon-alpha.
- *Br J Dermatol* 1997, 137(2):324-325. [PubMed Abstract](#)
- Berrazueta JR, Riestra A, Salas E, Poveda JJ, Fernandez-Llaca H, Navarro-Baldeweg O, Amado JA: Aquagenic pruritus response to the exogenous nitric oxide donor, transdermal nitroglycerin.
- *Int J Dermatol* 1994, 33(10):752-753. [PubMed Abstract](#) | [Publisher Full Text](#)
- Carson TE: Aquagenic pruritus: effective treatment with intramuscular triamcinolone acetonide.
- *Cutis* 1991, 48(5):382-383. [PubMed Abstract](#)
- Olumide YM, Oresanya F: Generalized pruritus as a presenting symptom in Nigeria.
- *Int J Dermatol* 1987, 26(3):171-3. [PubMed Abstract](#) | [Publisher Full Text](#)
- Potasman I, Heinrich I, Bassan HM: Aquagenic pruritus: prevalence and clinical characteristics.
- *Isr J Med Sci* 1990, 26(9):499-503. [PubMed Abstract](#)
- Dannaker CJ, Greenway H: Failure of sodium bicarbonate baths in the treatment of aquagenic pruritus.
- *J Am Acad Dermatol* 1989, 20(6):1136. [PubMed Abstract](#) | [Publisher Full Text](#)
- Spelman L, Dicker T: Aquagenic pruritus relieved by tight fitting clothing.
- *Australas J Dermatol* 2001, 42(2):146. [PubMed Abstract](#) | [Publisher Full Text](#)

- Goodkin R, Bernhard JD: Repeated PUVA treatment of aquagenic pruritus.
- *Clin Exp Dermatol* 2002, 27(2):164-165. [PubMed Abstract](#) | [Publisher Full Text](#)
- Rivard J, Lim HW: Ultraviolet phototherapy for pruritus.
- *Dermatol Ther* 2005, 18(4):344-354. [PubMed Abstract](#) | [Publisher Full Text](#)
- Norris JF: Treatment of aquagenic pruritus with alcohol.
- *Br J Dermatol* 1998, 138(5):927. [PubMed Abstract](#) | [Publisher Full Text](#)
- Frances AM, Fiorenza G, Frances RJ: Aquagenic urticaria: report of a case.
- *Allergy Asthma Proc* 2004, 25(3):195-7. [PubMed Abstract](#) | [Publisher Full Text](#)
- Parks A, Camisa C: Aquagenic angioedema.
- *Cutis* 1986, 37(6):465-6. [PubMed Abstract](#)
- Office of Rare Diseases Research. "[Aquagenic pruritus](#)". National Institute of Health. Retrieved 18 April 2012.
- Salami, TA; Samuel, SO; Eze, KC; Irekpita, E; Oziegbe, E; Momoh, MO (2009). "[Prevalence and characteristics of aquagenic pruritus in a young African population](#)". *BMC Dermatology* 9: 4. doi:10.1186/1471-5945-9-4. [PMC 2673209](#). [PMID 19374742](#).
- Santoso, Ivan; Santoso-Pham, Julia C. (September 1999). "[Aquagenic Pruritus: Two Cases That Resolved with Histamine₁ and Histamine₂ Antagonists](#)" (PDF). *Hospital Physician*: 67–8. "[Aquagenic Pruritus](#)". Family Practice Notebook. Retrieved 18 April 2012.
- Boodman, Sandra G. (May 16, 2011). "[Common symptom, uncommon cause](#)". *Washington Post*. Retrieved 3 Jul 2012.
- Sekine, R. et al. (Mar 2012). "Anti pruritic effects of topical crotamiton, capsaicin, and a corticosteroid on pruritogen-induced scratching behavior." 21 (3). pp. 201–4.
- Freedberg, Irwin M.; Eisen, Arthur Z.; Wolff, Klaus; Austen, K. Frank; Goldsmith, Lowell A.; Katz, Stephen I., eds. (2003). *Fitzpatrick's Dermatology in General Medicine* (6th ed.). McGraw-Hill. p. 401. ISBN 978-0-07-138066-9.
- James, William Daniel; Berger, Timothy G.; Elston, Dirk M. (2005). *Andrews' Diseases of the Skin: Clinical Dermatology* (10th ed.). Saunders. p. 56. ISBN 978-0-7216-2921-6.
- Sekar, Cshanmuga; Jacob, Sheja; Srinivas, CR (2011). "[Aquagenic pruritus: Beneath water 'lies'](#)". *Indian Journal of Dermatology* 56 (4): 446–7. doi:10.4103/0019-5154.84734. [PMC 3179019](#). [PMID 21965864](#).

- Nosbaum, Audrey; Pecquet, Catherine; Bayrou, Olivier; Amsler, Emmanuelle; Nicolas, Jean F.; Bérard, Frédéric; Francès, Camille (2011). "Treatment with propranolol of 6 patients with idiopathic aquagenic pruritus". *The Journal of Allergy and Clinical Immunology* 128 (5): 1113. doi:10.1016/j.jaci.2011.05.001. PMID 21616525.
- Holme, S. A.; Anstey, A. V. (2001). "Aquagenic pruritus responding to intermittent photochemotherapy". *Clinical and Experimental Dermatology* 26 (1): 40–1. doi:10.1046/j.1365-2230.2001.00757.x. PMID 11260176.
- People's Pharmacy. "Hot Water for Itches". Retrieved 25 July 2012.
- Ingber, Sarah; Cohen, Paul D. (2006). "Successful Treatment of Refractory Aquagenic Pruritus with Naltrexone". *Journal of Cutaneous Medicine and Surgery* 9 (5): 215–6. doi:10.1007/s10227-005-0144-x. PMID 16502200.
- Bayoumi, A.H. and Hight, A.S. Baking soda baths for aquagenic pruritus. *Lancet*. 1986; 2: 464
- Thomsen, K. Aquagenic pruritus responds to propranolol. *J Am Acad Dermatol*. 1990; 22: 697
- Bircher, A.J. and Meier-Ruge, W. Aquagenic pruritus. Water-induced activation of acetylcholinesterase. *Arch Dermatol*. 1988; 124: 84–89
- Misery, L., Meyronet, D., Pichon, M., Brutin, J., Pestre, P., and Cambazard, F. Aquadynie: rôle du VIP?. *Ann Dermatol Venereol*. 2003; 130: 195–198
- McGrath JA, Greaves MW. Aquagenic pruritus and the myelodysplastic syndrome. *Br J Dermatol* 1990; 123:414–415 PubMedView Article
- Newton JA, Singh AS, Greaves MW, et al. Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome. *Br J Dermatol* 1990; 122:103–106 PubMedView Article
- Ferguson JE, August PJ, Guy AJ. Aquagenic pruritus associated with metastatic squamous cell carcinoma of the cervix. *Clin Exp Dermatol* 1994; 19:257–258 PubMedView Article
- Greaves MW, Wall PD. Pathophysiology of itching. *Lancet* 1996; 348:938–940 PubMedView Article
- Summerfield JA. Naloxone modulates the perception of itch in man. *Br J Clin Pharmacol* 1980; 10:180–183 PubMed

- Ko MC, Song MS, Edwards T, et al. The role of central μ receptors in opioid induced itch in primates. *J Pharamcol Exp Ther* 2004 Jul; 310(1):169–176 [View Article](#)
- Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. *J Am Acad Dermatol* 1999 Oct; 41(4):533–539
- Shelley, Walter B. *Classics in Clinical Dermatology*. New York: Parthenon Publishing Group, 2003, pp 916–918
- Abdel Naser MB, Gollnick H, Orfanos CE. Aquagenic pruritus as a presenting symptom of polycythemia vera. *Dermatology*. 1993;187:130–3. [[PubMed](#)]
- Handfield-Jones SE, Hills RJ, Ive FA, Greaves MW. Aquagenic pruritus associated with juvenile xanthogranuloma. *Clin Exp Dermatol*. 1993;18:253–5. [[PubMed](#)]
- Khalifa N, Singer CR, Black AK. Aquagenic pruritus in a patient associated with myelodysplasia and T-cell non-Hodgkin's lymphoma. *J Am Acad Dermatol*. 2002;46:144–5. [[PubMed](#)]
- Gregor M. Aquagenic pruritus and hepatitis. *Internist (Berl)* 1999;40:220–1. [[PubMed](#)]
- Moreno Caballero B, Castro Barrio M, Blanco Andres C. Aquagenic pruritus due to use of bupropion. *Aten Primaria*. 2002;30:662–3. [[PubMed](#)]
- Newton JA, Singh AK, Greaves MW, Spry CJ. Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome. *Br J Dermatol*. 1990;112:103–6. [[PubMed](#)]
- Koh MJ, Chong WS. Aquagenic pruritus responding to combined ultraviolet A/narrowband ultraviolet B therapy. *Photodermatol Photoimmunol Photomed*. 2009;25:169–70. [[PubMed](#)]
- Ständer S, Streit M, Darsow U, Niemeier V, Vogelgsang M, Ständer H, et al. Diagnostisches und therapeutisches Vorgehen bei chronischem Pruritus. *J Dtsch Dermatol Ges* 2006; 4: 350–370.
- Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wie E, Bíró T. Neurphysiological, neuroimmunological, and neuroendocrine basis of pruritus. *J Invest Dermatol* 2006; 126: 1705–1718.
- Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15438 consecutive inpatients, 1975–1982. *J Am Med Assoc* 1986; 256: 3358–3363.

- van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. *J Clin Epidemiol* 1998; 51: 703–708.
- Raksha MP, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. *Indian J Dermatol Venereol Leprol* 2008; 74: 80
- Shirin H, Schapiro JM, Arber N, Pinkhas J, Sidi Y, Salomon F. Erythromycin base-induced rash and liver function disturbances. *Ann Pharmacother* 1992; 26: 1522–1523.
- Morton A, Muir J, Lim D. Rash and acute nephritic syndrome due to candesartan. *BMJ* 2004; 328: 25.
- Amaro P, Nunes A, Maçôas F, Ministro P, Baranda J, Cipriano A, et al. Ticlopidine-induced prolonged cholestasis: a case report. *Eur J Gastroenterol Hepatol* 1999; 11: 673–676.
- Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. *Gastroenterology* 1994; 107: 1844–1847.
- Mikhail NE. Methimazole-induced cholestatic jaundice. *South Med J* 2004; 97: 178–182.
- Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. *Endocr Pract* 2003; 9: 307–309.
- Quattropani C, Schneider M, Helbling A, Zimmermann A, Krähenbühl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. *Liver* 2001; 21: 213–216.
- Orme S, da Costa D. Generalized pruritus associated with amlodipine. *Br Med J* 1997; 315: 463.
- Odeh M, Oliven A. Verapamil-associated liver injury. *Harefuah* 1998; 134: 36–37.
- Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. *Gastroenterology* 1992; 102: 2148–2150.
- Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, et al. Amitriptyline-induced prolonged cholestasis. *Gastroenterology* 1988; 94: 200–203.
- Metze D, Reimann S, Szépfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. *Br J Dermatol* 1997; 136: 553–559.
- Weisshaar E. Evidence-based medicine and pruritus. (Abstr. OP4) *Acta Derm Venereol* 2007; 87: 462.

- Gavras H. A multicenter trial of enalapril in the treatment of essential hypertension. *Clin Ther* 1986; 9: 24–38.
- Mulinari R, Gavras I, Gavras H. Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. *Clin Ther* 1987; 9: 678–689.
- Nunes AC, Amaro P, Maçôas F, Cipriano A, Martins I, Rosa A, et al. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. *Eur J Gastroenterol Hepatol* 2001; 13: 279–282.
- Parker WA. Captopril-induced cholestatic jaundice. *Drug Intell Clin Pharm* 1984; 18: 234–235.
- Steckelings UM, Artuc M, Wollschläger T, Wiehstutz S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. *Acta Derm Venereol* 2001; 81: 321–325.
- Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. *Dan Med Bull* 1987; 34 Suppl 1: 3–5.
- Thind GS. Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics. *Cardiovasc Drugs Ther* 1990; 4: 199–206.
- Chitturi S, Farrell GC. Drug-induced cholestasis. *Semin Gastrointest Dis* 2001; 12: 113–124.
- Jeck T, Edmonds D, Mengden T, Schubert M, Renz I, Weisser B, et al. Betablocking drugs in essential hypertension: transdermal bupranolol compared with oral metoprolol. *Int J Clin Pharmacol Res* 1992; 12: 139–148.
- Hagemeyer KO, Stein J. Hepatotoxicity associated with carvedilol. *Ann Pharmacother* 2001; 35: 1364–1366.
- Bernink PJ, de Weerd P, Ten CF, Remme WJ, Barth J, Enthoven R, et al. An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. *J Cardiovasc Pharmacol* 1991; 17 Suppl 1: S53–S56.
- Gonzalo Garijo MA, Pérez Calderón R, de Argila Fernández-Durán D, Rangel-Mayoral JF. Cutaneous reactions due to diltiazem and cross reactivity with other calcium channel blockers. *Allergol Immunopathol (Madr)* 2005; 33: 238–240.
- Burgunder JM, Abernethy DR, Lauterburg BH. Liver injury due to verapamil. *Hepato-gastroenterology* 1988; 35: 169–170.

- Haider Z, Bano KA. Experience with anti-hypertensive drug therapy in a hypertension Clinic – 1972–1983. A retrospective analysis. *J Pak Med Assoc* 1990; 40: 91–93.
- Wolfhagen FH, Vermeulen HG, de Man RA, Lesterhuis W. Initially obscure hepatotoxicity attributed to sildenafil. *Eur J Gastroenterol Hepatol* 2008; 20: 710–712.
- Salti Z, Cloche P, Weber P, Haussemand G, Vollmer F. A case of cholestatic hepatitis caused by amiodarone. *Ann Cardiol Angiol (Paris)* 1989; 38: 13–16.
- MacLaughlin EJ, Fitzpatrick KT, Sbar E, Jewell C. Anaphylactoid reaction to enoxaparin in a patient with deep venous thrombosis. *Pharmacotherapy* 2002; 22: 1511–1515.
- Kilo C, Dudley J, Kalb B. Evaluation of the efficacy and safety of Diamicon in non-insulin-dependent diabetic patients. *Diabetes Res Clin Pract* 1991; 14 Suppl 2: 79–82.
- Stewart RD, Anderson DE. Glycodiazine in diabetes mellitus: a clinical trial. *Br Med J* 1965; 2: 682–684.
- Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. *Am J Cardiol* 2002; 89: 672–678.
- Sharma M, Sharma DR, Singh V, Panwar RB, Hira HS, Mohan B, et al. Evaluation of efficacy and safety of fixed dose lovastatin and niacin (ER) combination in asian Indian dyslipidemic patients: a multicentric study. *Vasc Health Risk Manag* 2006; 2: 87–93.
- Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L. Simvastatin-induced lichen planus pemphigoides. *Ann Dermatol Venereol* 2003; 130: 187–190.
- Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. *N Engl J Med* 1985; 312: 1229–1232.
- Adcock BB, Rodman DP. Ampicillin-specific rashes. *Arch Fam Med* 1996; 5: 301–304.
- Shimokata K, Suetsugu S, Umeda H, Inada S, Torikai K, Morishita M, et al. Evaluation of T-2588 in the treatment of respiratory tract infection. *Jpn J Antibiot* 1986; 39: 2897–2913.

- Sonoda T, Matsuda M, Nakano E, Mizutani S, Iwao N, Miyoshi S, et al. Clinical evaluation of cefixime (CFIX) in the treatment of urinary tract infection. *Hinyokika Kyo* 1989; 35: 1267–1275.
- Theopold M, Benner U, Bauernfeind A. Effectiveness and tolerance of cefixime in bacterial infections in the ENT area. *Infection* 1990; 18 Suppl 3: S122–S124.
- Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M. Hepatotoxicity by amoxicillin/clavulanic acid: case report. *Rev Med Chil* 1999; 127: 1487–1491.
- Gonzalo-Garijo MA, de Argila D. Erythroderma due to aztreonam and clindamycin. *Investig Allergol Clin Immunol* 2006; 16: 210–211.
- Cook JA, Silverman MH, Schelling DJ, Nix DE, Schentag JJ, Brown RR, et al. Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. *Antimicrob Agents Chemother* 1990; 34: 974–979.
- Cox CE. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. *Am J Med* 1992; 92: 82S–86S.
- Williams DJ, Hopkins S. Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin. *Am J Surg* 1998; Suppl 176: 74S–79S.
- Ball P. Ciprofloxacin: an overview of adverse experiences. *J Antimicrob Chemother* 1986; 18 Suppl D: 187–193.
- Hessen MT, Ingerman MJ, Kaufman DH, Weiner P, Santoro J, Korzeniowski OM, et al. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. *Am J Med* 1987; 82: 262–265.
- Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. *Br J Dermatol* 1996; 134: 693–695.
- Report to the Research Committee of the British Tuberculosis Association by the Clinical Trials Subcommittee. Comparison of side-effects of tetracycline and tetracycline plus nystatin. *Br Med J* 1968; 4: 11–15.
- Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. *World J Gastroenterol* 2007; 13: 5408–5410.
- Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. *Drugs* 1999; 58: 1061–1097.

- Kapoor K, Chandra M, Nag D Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: a prospective study. *Int J Clin Pharmacol Res* 1999; 19: 83–88.
- Walker-Renard P. Pruritus associated with intravenous rifampin. *Ann Pharmacother* 1995; 29: 267–268.
- Siboulet A, Bohbot JM, Lhuillier N, Siboulet A, Catalan F. “One-minute treatment” with thiamphenicol in 50,000 cases of gonorrhoea: a 22-year study. *Sex Transm Dis* 1984; 11 Suppl 4: 391–395.
- Ruskin J, LaRiviere M. Low-dose co-trimoxazole for prevention of *Pneumocystis carinii* pneumonia in human immunodeficiency virus disease. *Lancet* 1991; 337: 468–471.
- Adebayo RA, Sofowora GG, Onayemi O, Udoh SJ, Ajayi AA. Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. *Br J Clin Pharmacol* 1997; 44: 157–161.
- Ajayi AA, Kolawole BA, Udoh SJ. Endogenous opioids, μ -opiate receptors and chloroquine-induced pruritus: A double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching. *Int J Dermatol* 2004; 43: 972–977.
- Ekpechi OL, Okoro AN. A pattern of pruritus due to chloroquine. *Arch Dermatol* 1964; 89: 631–632.
- Olayemi O, Fehintola FA, Osungbade A, Aimakhu CO, Udoh ES, Adeniji AR. Pattern of chloroquine-induced pruritus in antenatal patients at the University College Hospital, Ibadan. *J Obstet Gynaecol* 2003; 23: 490–495.
- Bussaratid V, Walsh DS, Wilairatana P, Krudsood S, Silachamroon U, Looareesuwan S. Frequency of pruritus in *Plasmodium vivax* malaria patients treated with chloroquine in Thailand. *Trop Doct* 2000; 30: 211–214.
- Spencer HC, Poulter NR, Lury JD, Poulter CJ. Chloroquine associated pruritus in a European. *BMJ* 1982; 285: 1703.
- Kaseje DC, Sempebwa EK, Spencer HC. Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. Reason for non-acceptance. *Ann Trop Med Parasitol* 1987; 81: 77–82.

- Ezeamuzie IC, Igbigbi PS, Ambakederemo AW, Abila B, Nwaejike IN. Halofantrine-induced pruritus amongst subjects who itch to chloroquine. *J Trop Med Hyg* 1991; 94: 184–188.
- Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. *Acta Derm Venereol* 1999; 79: 333.
- Jiménez-Alonso J, Tercedor J, Jáimez L, García-Lora E. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus. *Arthritis Rheum* 1998; 48: 744–745.
- Jiménez-Alonso J, Tercedor J, Reche I. Antimalarial drugs and pruritus in patients with lupus erythematosus. *Acta Derm Venereol* 2000; 80: 458.
- Osifo NG. The antipruritic effects of chlorpheniramine, cyproheptadine and sulphapyridine monitored with limb activity meters on chloroquine induced pruritus among patients with malaria. *Afr J Med Med Sci* 1995; 24: 67–73.
- Ademowo OG, Sodeine O, Walker O. The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus. *Clin Pharmacol Ther* 2000; 67: 237–241.
- Onyeji CO, Ogunbona FA. Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. *Eur J Pharm Sci* 2001; 13: 195–201.
- Onigbogi O, Ajayi AA, Ukponmwan OE. Mechanism of chloroquine-induced body scratching behavior in rats: evidence of involvement of endogenous opioid peptides. *Pharmacol Biochem Behav* 2000; 65: 333–337.
- Ajayi AA, Akinleye AO, Udoh SJ, Ajayi OO, Oyelese O, Ijaware CO. The effect of prednisolone and niacin on chloroquine-induced pruritus in malaria. *Eur J Clin Pharmacol* 1991; 41: 383–385.
- Cederberg J, Knight S, Svenson S, Melhus H. Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report. *B M C Psychiatry* 2004; 4: 36.
- Richard MA, Fiszenson F, Jreissati M, Jean Pastor MJ, Grob JJ. Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases. *Ann Dermatol Venereol* 2001; 128: 759–761.
- Chlumská A, Curík R, Boudová L, Mukensnabl P, Klvana P. Chlorpromazine-induced cholestatic liver disease with ductopenia. *Cesk Patol* 2001; 37: 118–122.

- Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. *Hepatology* 1994; 20: 1437–1441.
- Radzik J, Grotthus B, Leszek J. Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment – case report. *Psychiatr Pol* 2005; 39: 309–313.
- Regal RE, Billi JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. *Clin Pharm* 1987; 6: 787–794.
- Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. *Clin Pharmacokinet* 2003; 42: 33–58.
- Knapp LE, Kugler AR. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. *J Child Neurol* 1998; 13 Suppl 1: S15–S18.
- Ochoa JG. Pruritus, a rare but troublesome adverse reaction of topiramate. *Seizure* 2003; 12: 516–518.
- Prosser TR, Lander RD. Phenytoin-induced hypersensitivity reactions. *Clin Pharm* 1987; 6: 728–734.
- Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. *C N S Drugs* 2001; 15: 137–163.
- Torricelli R, Kurer SB, Kroner T, Wüthrich B. Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review. *Schweiz Med Wochenschr* 1995; 125: 1870–1873.
- Dunphy FR, Boyd JH, Kim HJ, Dunphy CH, Harrison BR, Dunleavy TL, et al. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. *Cancer* 1997; 79: 2016–2023.
- Freilich RJ, Seidman AD. Pruritis caused by 3-hour infusion of high-dose paclitaxel and improvement with tricyclic antidepressants. *J Natl Cancer Inst* 1995; 87: 933–934.
- Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). *Ann Oncol* 2006; 17: 1007–1013.

- Love RR, Nguyen BD, Nguyen CB, Nguyen VD, Havighurst TC. Symptoms associated with oophorectomy and tamoxifen treatment for breast cancer in premenopausal Vietnamese women. *Breast Cancer Res Treat* 1999; 58: 281–286.
- Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. *J Clin Oncol* 1994; 12: 2667–2676.
- Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, et al. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. *Oncology* 2001; 60: 110–115.
- Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. *J Am Med Assoc* 1987; 258: 1624–1629.
- Redman BG, Flaherty L, Chou TH, al-Katib A, Kraut M, Martino S, et al. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. *J Clin Oncol* 1990; 8: 1269–1276.
- Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. *Breast Cancer Res Treat* 2009; 114: 485–493.
- Bork K. Pruritus precipitated by hydroxyethyl starch: a review. *Br J Dermatol* 2005; 152: 3–12.
- Bode U, Deisseroth AB. Donor toxicity in granulocyte collections: association of lichen planus with the use of hydroethyl starch leukapheresis. *Transfusion* 1981; 21: 83–85.
- Parker NE, Porter JB, Williams HJ, Leftley N. Pruritus after administration of hetastarch. *Br Med J (Clin Res Ed)* 1982; 284: 385–386.
- Schneeberger R, Albegger K, Oberascher G, Miller K. Pruritus – a side effect of hydroxyethyl starch? First report. *HNO* 1990; 38: 298–303.
- Albegger K, Schneeberger R, Franke V, Oberascher G, Miller K. Itching following therapy with hydroxyethyl starch (HES) in otoneurological diseases. *Wien Med Wochenschr* 1992; 142: 1–7.
- Jurecka W, Szépfalusi Z, Parth E, Schimetta W, Gebhart W, Scheiner O, et al. Hydroxyethylstarch deposits in human skin – a model for pruritus? *Arch Dermatol Res* 1993; 285: 13–19.

- Gall H, Schultz KD, Boehncke WH, Kaufmann R. Clinical and pathophysiological aspects of hydroxyethyl starch-induced pruritus: evaluation of 96 cases. *Dermatology* 1996; 192: 222–226.
- Sharland C, Hugett A, Nielson MS, Friedmann PS. Persistent pruritus after pentastarch infusions in intensive care patients. *Anaesthesia* 1999; 54: 500–501.
- Morgan PW, Berridge JC. Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. *Br J Anaesth* 2000; 85: 696–699.
- Murphy M, Carmichael AJ, Lawler PG, White M, Cox NH. The incidence of hydroxyethyl starch-associated pruritus. *Br J Dermatol* 2001; 144: 973–976.
- Kimme P, Janssen B, Ledin T, Gupta A, Vegfors M. High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions. *Acta Anaesthesiol Scand* 2001; 45: 686–689.
- Roll A, Wüthrich B, Schmid-Grendelmeier P, Hofbauer G, Ballmer-Weber BK. Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. *Swiss Med Wkly* 2006; 136: 684–690.
- Thumb N, Kolarz G, Scherak O, Mayrhofer F. The efficacy and safety of fentiazac and diclofenac sodium in peri-arthritis of the shoulder: a multi-centre, double-blind comparison. *J Int Med Res* 1987; 15: 327–334.
- Chamouard P, Walter P, Baumann R, Paupon R. Prolonged cholestasis associated with short-term use of celecoxib. *Gastroenterol Clin Biol* 2005; 29: 1286–1288.
- Topal F, Ozaslan E, Akbulut S, Küçükazman M, Yüksel O, Altiparmak E. Methylprednisolone-induced toxic hepatitis. *Ann Pharmacother* 2006; 40: 1868–1871.
- Lieberman DA, Keefe EB, Stenzel P. Severe and prolonged oral contraceptive jaundice. *J Clin Gastroenterol* 1984; 6: 145–148.
- Medline A, Ptak T, Gryfe A, Blenkinsop B. Pruritus of pregnancy and jaundice induced by oral contraceptives. *Am J Gastroenterol* 1976; 65: 156–159.
- Velayudham LS, Farrell GC. Drug-induced cholestasis. *Expert Opin Drug Saf* 2003; 2: 287–304.
- Swegle JM, Logemann C. Management of common opioid-induced adverse effects. *Am Pharm Phys* 2006; 74: 1347–1354.
- Chamberlin KW, Cottle M, Neville R, Tan J. Oral oxymorphone for pain management. *Ann Pharmacother* 2007; 41: 1144–1152.

- de Beer Jde V, Winemaker MJ, Donnelly GA, Miceli PC, Reiz JL, Harsanyi Z, et al. Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. *Can J Surg* 2005; 48: 277–283.
- Hadi MA, Kamaruljan HS, Saedah A, Abdullah NM. A comparative study of intravenous patient-controlled analgesia morphine and tramadol in patients undergoing major operation. *Med J Malaysia* 2006; 61: 570–576.
- Jacobson L, Chabal C, Brody MC, Ward RJ, Wasse L. Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg. *Pain* 1990; 43: 141–148.
- Lane S, Evans P, Arfeen Z, Misra U. A comparison of intrathecal fentanyl and diamorphine as adjuncts in spinal anaesthesia for Caesarean section. *Anaesthesia* 2005; 60: 453–457.
- Möhrenschrager M, Glöckner A, Jessberger B, Worret WI, Ollert M, Rakoski J, et al. Codeine caused pruritic scarlatiniform exanthemata: patch test negative but positive to oral provocation test. *Br J Dermatol* 2000; 143: 663–664.
- Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: a role for 5-HT₃ antagonists? *Br J Anaesth* 1999; 82: 439–441.
- Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. *J Clin Anesth* 2003; 15: 234–239.
- Herman NL, Choi KC, Affleck PJ, Calicott R, Brackin R, Singhal A, et al. Analgesia, pruritus, and ventilation exhibit a dose-response relationship in parturients receiving intrathecal fentanyl during labor. *Analgesia Anesth* 1999; 89: 378–383.
- Ko MC, Song MS, Edwards T, Lee H, Naughton NN. The role of central μ opioid receptors in opioid-induced itch in primates. *J Pharmacol Exp Ther* 2004; 310: 169–176.
- Thomas DA, Hammond DL. Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. *Brain Res* 1995; 695: 267–270.
- Thomas DA, Williams GM, Iwata K, Kenshalo DR Jr, Dubner R. The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys. *Anesthesiology* 1993; 79: 548–554.

- Tohda C, Yamaguchi T, Kuraishi Y. Intracisternal injection of opioids induces itch-associated response through μ -opioid receptor in mice. *Jpn J Pharmacol* 1997; 74: 77–82.
- Waxler B, Dadabhoy ZP, Stojiljkovic L, Rabito SF. Primer of postoperative pruritus for anesthesiologists. *Anesthesiology* 2005; 103: 168–178.
- Fitzgerald DA, Heagerty AH, Stephens M, Smith AG. Follicular toxic pustuloderma associated with allopurinol. *Clin Exp Dermatol* 1994; 19: 243–245.
- Miró N. Controlled multicenter study on chronic suppurative otitis media treated with topical applications of ciprofloxacin 0.2% solution in single-dose containers or combination of polymyxin B, neomycin, and hydrocortisone suspension. *Otolaryngol Head Neck Surg* 2000; 123: 617–623.
- Szepietowski J, Reich A, Białynicki-Birula R. Itching in atopic dermatitis: clinical manifestation, pathogenesis and the role of pimecrolimus in itch reduction. *Dermatol Klin* 2004; 6: 173–176.
- Kjellberg F, Tramèr MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. *Eur J Anaesthesiol* 2001; 18: 346–357.
- Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. *J Am Acad Dermatol* 1999; 41: 533–539.
- Szeimies RM, Stolz W, Wlotzke U, Korting HC, Landthaler M. Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. *Br J Dermatol* 1994; 131: 380–382.
- Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, Zylicz Z. Itch: scratching more than the surface. *QJM* 2003; 96: 7–26.
- Kremer AE, Beuers U, Oude-Elferink RPJ, Puhl T. Pathogenesis and treatment of pruritus in cholestasis. *Drugs* 2008; 68: 2163–2182.
- George AO. Chloroquine induced pruritus – questionnaire based epidemiological study. *Afr J Health Sci* 2004; 11: 87–92.
- Olayemi O, Fehintola FA, Osungbade A, Aimakhu CO, Udoh ES, Adeniji AR. Pattern of chloroquine-induced pruritus in antenatal patients at the University College Hospital, Ibadan. *J Obstet Gynaecol.* 2003; 23: 490–495.

- Ademowo OG, Sodeinde O. Certain red cell genetic factors and prevalence of chloroquine-induced pruritus. *Afr J Med Med Sci* 2002; 31: 341–343.
- Ständer S, Böckenholt B, Schürmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol* 2009; 89: 45–51.
- Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT₃) receptor antagonist reduce experimentally-induced itch? *Inflamm Res* 1997; 46: 412–416.
- Tonnesen P, Schaffalitzky de Muckadell OB, Mygind N. Nasal challenge with serotonin in asymptomatic hay fever patients. *Allergy* 1987; 42: 447–450.
- Charuluxananan S, Kyokong O, Somboonviboon W, Lertmaharit S, Ngamprasertwong P, Nimcharoendee K. Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritus after cesarean delivery. *Anesth Analg* 2001; 93: 162–165.
- Charuluxananan S, Kyokong O, Somboonviboon W, Narasethakamol A, Promlok P. Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. *Anesth Analg* 2003; 96: 1789–1793.
- Kendrick WD, Woods AM, Daly MY, Birch RF, DiFazio C. Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. *Anesth Analg* 1996; 82: 641–647.
- Okutomi T, Saito M, Mochizuki J, Amano K. Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients. *Can J Anesth* 2003; 50: 961–962.
- Nakatsuka N, Minogue SC, Lim J, Montgomery CJ, Court CA, Malherbe S, Csanyi-Fritz Y, et al. Intravenous nalbuphine 50 microg x 1 kg⁽⁻¹⁾ is ineffective for opioid-induced pruritus in pediatrics. *Can J Anaesth* 2006; 53: 1103–1110.
- Han DW, Hong SW, Kwon JY, Lee JW, Kim KJ. Epidural ondansetron is more effective to prevent postoperative pruritus and nausea than intravenous ondansetron in elective cesarean delivery. *Acta Obstet Gynecol Scand* 2007; 86: 683–687.
- Iatrou CA, Dragoumanis CK, Vogiatzaki TD, Vretzakis GI, Simopoulos CE, Dimitriou VK. Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blind, placebo-controlled study. *Anesth Analg* 2005; 101: 1516–1520.

- Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. *Pharmacotherapy* 1996; 16: 958–960.
- Korhonen AM, Valanne JV, Jokela RM, Ravaska P, Kortilla K. Ondansetron does not prevent pruritus induced by low-dose intrathecal fentanyl. *Acta Anaesthesiol Scand* 2003; 47: 1292–1297.
- Waxler B, Mondragon SA, Patel S, Nedumgottil K. Prophylactic ondansetron does not reduce the incidence of itching induced by intrathecal sufentanil. *Can J Anesth* 2004; 51: 685–689.
- Wells J, Paech MJ, Evans SF. Intrathecal fentanyl-induced pruritus during labour: the effect of prophylactic ondansetron. *Int J Obstet Anesth* 2004; 13: 35–39.
- Horta ML, Morejon LC, da Cruz AW, Dos Santos GR, Welling LC, Terhorst L, et al. Study of the prophylactic effect of droperidol, alizapride, propofol and promethazine on spinal morphine-induced pruritus. *Br J Anaesth* 2006; 96: 796–800.
- Sheen MJ, Ho ST, Lee CH, Tsung YC, Chang FL. Preoperative gabapentin prevents intrathecal morphine-induced pruritus after orthopedic surgery. *Anesth Analg* 2008; 106: 1868–1872.
- Demiraran Y, Ozdemir I, Kocaman B, Yucel O. Intrathecal sufentanil (1.5 µg) added to hyperbaric bupivacaine (0.5%) for elective cesarean section provides adequate analgesia without need for pruritus therapy. *J Anaesth* 2006; 20: 274–278.
- Reimann S, Szépfalusi Z, Kraft D, Luger T, Metze D. Hydroxyethyl starch accumulation in the skin with special reference to hydroxyethyl starch-associated pruritus. *Dtsch Med Wochenschr* 2000; 125: 280–285.
- Ständer S, Szépfalusi Z, Bohle B, Ständer H, Kraft D, Luger TA, Metze D. Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study. *Cell Tissue Res* 2001; 304: 261–269.